Last reviewed · How we verify
NN1218
At a glance
| Generic name | NN1218 |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (PHASE3)
- A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes (PHASE1)
- A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes (PHASE1)
- A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes (PHASE1)
- A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes (PHASE1)
- A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Diabetes Mellitus, Type 1 (PHASE1)
- A Trial Investigating NN1218 in Subjects With Type 1 Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NN1218 CI brief — competitive landscape report
- NN1218 updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI